{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:40:46Z","timestamp":1767829246380,"version":"3.49.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.coviro.2018.10.005","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T19:34:50Z","timestamp":1542051290000},"page":"115-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Viral resistance in HCV infection"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-5101","authenticated-orcid":false,"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Cento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velia Chiara","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Crax\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2018.10.005_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0015","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coviro.2018.10.005_bib0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","article-title":"The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control","volume":"65","author":"Bukh","year":"2016","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.coviro.2018.10.005_bib0025","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C Virus into 8 gnotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.coviro.2018.10.005_bib0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0035","series-title":"Recommendations for Testing, Managing, and Treating Hepatitis C","author":"AASLD-IDSA","year":"2017"},{"key":"10.1016\/j.coviro.2018.10.005_bib0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2055-6640(20)30267-3","article-title":"The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C","volume":"4","author":"Popping","year":"2018","journal-title":"J Virus Erad"},{"key":"10.1016\/j.coviro.2018.10.005_bib0045","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/apt.14527","article-title":"Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA","volume":"47","author":"Chhatwal","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coviro.2018.10.005_bib0050","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0055","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.10.005_sbref0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/liv.13534","article-title":"Sofosbuvir\/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.coviro.2018.10.005_bib0070","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2018.10.005_bib0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/jvh.12795","article-title":"Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4","volume":"25","author":"Camus","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2018.10.005_bib0080","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","author":"Smith","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0085","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3851\/IMP2529","article-title":"A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy","volume":"18","author":"Cento","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2018.10.005_bib0090","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3851\/IMP3130","article-title":"HCV intergenotype 2k\/1b recombinant detected in a DAA-treated patient in Italy","volume":"22","author":"Paolucci","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2018.10.005_bib0095","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3228","article-title":"HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era","author":"Minichini","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2018.10.005_bib0100","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jhep.2017.09.008","article-title":"Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?","volume":"68","author":"Di Maio","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0105","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0110","article-title":"Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r","author":"Fourati","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_sbref0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist"},{"key":"10.1016\/j.coviro.2018.10.005_bib0120","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0125","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.10.005_bib0140","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy","volume":"67","author":"Vicenti","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2018.10.005_bib0145","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.28422","article-title":"Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)","volume":"64","author":"Lawitz","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2018.10.005_bib0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.10.005_sbref0160","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/hep.29693","article-title":"Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives","volume":"67","author":"Harrington","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0165","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3237","article-title":"Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals","author":"Palanisamy","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2018.10.005_bib0170","doi-asserted-by":"crossref","first-page":"8988","DOI":"10.1038\/s41598-018-26862-y","article-title":"Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1\u20134 in Italy","volume":"8","author":"Bertoli","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.10.005_bib0175","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_sbref0180","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0185","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiv379","article-title":"NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection","volume":"213","author":"Zhou","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.10.005_bib0190","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hep.28611","article-title":"Hepatitis C genotype 4R resistance-associated polymorphisms: the achilles heel of the nonstructural 5A inhibitors?","volume":"64","author":"Halfon","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/apt.12551","article-title":"Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6","volume":"39","author":"Wantuck","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coviro.2018.10.005_bib0200","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/apt.14428","article-title":"Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt","volume":"47","author":"Omar","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.coviro.2018.10.005_bib0205","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir: integrated analysis of HCV genotype 1-6 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_sbref0210","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11904-017-0369-5","article-title":"Resistance to DAAs: when to look and when it matters","volume":"14","author":"Wyles","year":"2017","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.coviro.2018.10.005_bib0215","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.dld.2017.03.027","article-title":"Treatment of hepatitis C virus infection in Italy: a consensus report from an expert panel","volume":"49","author":"Vigano","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.coviro.2018.10.005_bib0220","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40506-017-0136-6","article-title":"Retreatment options following HCV direct-acting antiviral failure","volume":"9","author":"Zuckerman","year":"2017","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.coviro.2018.10.005_bib0225","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2018.10.005_sbref0230","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/hep.29601","article-title":"Benefit-risk assessment for sofosbuvir\/velpatasvir\/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. food and drug administration\u2019s evaluation","volume":"67","author":"Struble","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0235","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14656566.2018.1454428","article-title":"Protease inhibitor therapy for hepatitis C virus-infection","volume":"19","author":"de Leuw","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.coviro.2018.10.005_bib0240","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/hepr.12645","article-title":"JSH Guidelines for the management of hepatitis C Virus infection: a 2016 update for genotype 1 and 2","volume":"46","author":"Asahina","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.coviro.2018.10.005_bib0245","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","article-title":"Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir","volume":"152","author":"Komatsu","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C Virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coviro.2018.10.005_bib0255","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0260","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/jvh.12657","article-title":"NS5A inhibitors for the treatment of hepatitis C infection","volume":"24","author":"Gitto","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2018.10.005_bib0265","first-page":"103","article-title":"Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens","volume":"25","author":"Wyles","year":"2017","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.coviro.2018.10.005_bib0270","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2018.10.005_bib0275","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2018.06.021","article-title":"Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV\/HCV-coinfected MSM with risk of onward transmission","volume":"69","author":"Newsum","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.10.005_bib0280","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","article-title":"L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions","volume":"213","author":"Svarovskaia","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.10.005_bib0285","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12986","article-title":"Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals","author":"Perpi\u00f1\u00e1n","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2018.10.005_bib0290","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0295","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cid\/cix916","article-title":"Retreatment with sofosbuvir plus grazoprevir\/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 revenge study","volume":"66","author":"de L\u00e9dinghen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2018.10.005_bib0300","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2147\/IDR.S156581","article-title":"Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse","volume":"11","author":"Bonsall","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.coviro.2018.10.005_bib0305","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low- level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.10.005_bib0310","first-page":"632A","volume":"66","author":"Dvory-Sobo","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.10.005_bib0315","unstructured":"FDA Microbiology Review Maviret_209394Orig1s000MicroR. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209394Orig1s000MicroR.pdf."},{"key":"10.1016\/j.coviro.2018.10.005_bib0320","unstructured":"FDA Zepatier Microbiology\/Virology Review_208261Orig1s000MicroR. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208261Orig1s000MicroR.pdf."},{"key":"10.1016\/j.coviro.2018.10.005_bib0325","unstructured":"FDA NDA Microbiology\/Virology Review Veikira Pak_206619Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204671Orig1s000MicroR.pdf."},{"key":"10.1016\/j.coviro.2018.10.005_bib0330","unstructured":"FDA NDA Microbiology Virology Reviews_DCV+SOF_206843Orig1s001, s003. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208341Orig1s000MicroR.pdf."},{"key":"10.1016\/j.coviro.2018.10.005_bib0335","unstructured":"FDA Microbiology\/Virology Reviews Epclusa_ 208341Orig1s000 (2015). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208341Orig1s000MicroR.pdf."}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718300208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718300208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:02:52Z","timestamp":1761818572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625718300208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":67,"alternative-id":["S1879625718300208"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2018.10.005","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral resistance in HCV infection","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2018.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}